Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.
about
Immunotherapy for lung cancer: advances and prospectsEngineered T cells for cancer treatmentA novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.Cancer subclonal genetic architecture as a key to personalized medicine.Adoptive immunotherapy for cancer.Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.Biomedical techniques in translational studies: The journey so far.ErbB-targeted CAR T-cell immunotherapy of cancer.CAR T-cell immunotherapy: The path from the by-road to the freeway?Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies.Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity.Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinomaThe efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis.PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
P2860
Q26750617-0E61A5EF-843E-43D8-8D7E-4764F426C697Q33578792-05594978-FD1D-4234-BCBA-AA79F26C0AEEQ34729692-599CD1D8-F063-4514-9CA4-CAEA30F8A779Q37448116-B6A911F1-DAD1-4AB2-93A5-42B0FEFE8548Q38170496-514464B8-C41C-4388-AD47-2EC31C5FB3FBQ38172182-2369D5C9-0918-46BD-8B97-14ECAFDB377DQ38208852-B2BED3AE-CEAD-4CDC-923F-A95B6E1567E4Q38389298-043D6F72-D2FB-4B20-816B-1760B3FFA3A3Q38632105-E4CF3489-974E-4166-A344-17FD21F1B391Q38770555-B98742DE-1EE9-4022-A629-6A9CAA8F2D18Q38783833-3E0D3B8A-D929-42C5-B1AE-8F19E4065DA5Q38786626-8582B005-34AA-4A09-BA02-E286B1CC5A3FQ38834059-34226379-4DBC-4A12-818B-B52FE9FFF774Q38857075-DE62FABC-B12E-4CBC-90AB-ED7548B3F923Q39924228-A52F793F-8FDA-4A52-B8AE-01D3F2C54BFFQ45918458-4A270583-5BAA-49B2-B7B2-F2065A1A132CQ47920923-D2C689D5-5BBA-402B-83A7-345FF0D23CB7Q48098689-D053BA91-6BD8-4D39-8D15-693ADD81254BQ48507616-168D5C1A-0EE8-4183-955D-0E261634D45DQ50042810-EEBBF44A-AFCE-49FA-A532-654F9761E165
P2860
Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cellular immunotherapy for car ...... d EGFR-specific T lymphocytes.
@ast
Cellular immunotherapy for car ...... d EGFR-specific T lymphocytes.
@en
type
label
Cellular immunotherapy for car ...... d EGFR-specific T lymphocytes.
@ast
Cellular immunotherapy for car ...... d EGFR-specific T lymphocytes.
@en
prefLabel
Cellular immunotherapy for car ...... d EGFR-specific T lymphocytes.
@ast
Cellular immunotherapy for car ...... d EGFR-specific T lymphocytes.
@en
P2093
P2860
P356
P1433
P1476
Cellular immunotherapy for car ...... d EGFR-specific T lymphocytes.
@en
P2093
Kaijun Cui
Nongyu Huang
Xikun Zhou
Yinbing Zhang
Yu-quan Wei
P2860
P304
P356
10.1593/NEO.13168
P577
2013-05-01T00:00:00Z